Company Description
enVVeno Medical Corporation, a clinical-stage medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease.
The company’s lead product is the VenoValve, a replacement venous valve for the treatment of venous chronic venous insufficiency.
Its VenoValve implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh.
The company also develops enVVe, a non-surgical and transcatheter-based replacement venous valve system consisting of the enVVe valve, enVVe delivery system, and delivery system accessories.
The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021.
enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.
| Country | United States |
| Founded | 1987 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 37 |
| CEO | Robert Berman |
Contact Details
Address: 70 Doppler Irvine, California 92618 United States | |
| Phone | 949 261 2900 |
| Website | envveno.com |
Stock Details
| Ticker Symbol | NVNO |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001661053 |
| CUSIP Number | 29415J106 |
| ISIN Number | US29415J1060 |
| Employer ID | 33-0936180 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Robert A. Berman | Chief Executive Officer and Director |
| Dr. Hamed Alavi Ph.D. | Senior Vice President and Chief Technology Officer |
| Dr. Marc H. Glickman M.D. | Senior Vice President and Chief Medical Officer |
| Jennifer Bright CPA | Chief Financial Officer |
| Sandy Prietto | Vice President of Marketing |
| Andrew Cormack | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 2, 2025 | DEFR14A | Filing |
| Nov 20, 2025 | 8-K | Current Report |
| Nov 19, 2025 | PRER14A | Filing |
| Nov 19, 2025 | SCHEDULE 13G | Filing |
| Nov 14, 2025 | SCHEDULE 13G/A | Filing |
| Nov 14, 2025 | 8-K | Current Report |
| Oct 30, 2025 | 8-K | Current Report |
| Oct 30, 2025 | 424B5 | Filing |
| Oct 30, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Oct 30, 2025 | DEF 14A | Other definitive proxy statements |